SBIR/STTR Research Award

Discovering Novel Drug Targets for CNS Edema by In Vitro Genetics

Award identifier 2a0ac757c7eb9cbfc2c83427ac420d12b23c6f564ca46731b471fa035ee27f6bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,492,650

Program and phase

SBIR · Phase II

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PREDICTIVE BIOLOGY
Proposal award date
2018-09-30
Contract end date
2020-08-31
UEI
F1PNSXJZC269
Solicitation number
PA18-574
Topic code
NINDS

Research abstract

AbstractBrain swelling is a serious complication of traumatic brain injuryTBIischemic stroke and other serious conditionsTBI and stroke afflictM andK persons per year in the US aloneThey are a costly health care burden and a devastating social burdenCurrent treatments for brain swelling are limited and generally ineffectivehighlighting the dramatic unmet need for better therapeuticsA better understanding of the molecular pathways and cellular mechanisms is sorely needed to identify new drug targets and predictive biomarkers that can stratify patients for clinical treatment decisionsThe goal of this project is to identify new drug targets and biomarkers of response for cytotoxic edema of astrocytesWe will use a novel and innovative technology that we have developed that takes an unbiased approach to functionally identifying the causal mediators of brain cell swellingOur approach uses a large panel of genetically diverse astrocyte lines to identify the genes and pathways that mechanistically underlie cytotoxic edemaIn Phase Iwe developed a high throughput kinetic assay for astrocyte swelling that is robust and scalable for screening compounds that induce or block swellingIn Phase II we will screengenetically diverse astrocyte cell lines and then map and identify the genes that mediate response to inducers and blockers of cell swellingValidation of candidate target genes will be conducted in both human and mouse astrocytesHuman genes that modify human astrocyte response that are also therapeutically accessible target genes for novel drug discovery are the ultimate aims and products of this project Brain swellingcerebral edemais a serious consequence of many disorders such as traumatic brain injury and strokeA more complete understanding of the molecular pathways underlying cerebral edema is a critical bottleneck in the development of new drugs for brain swellingWe want to understand the molecular mechanisms underlying swelling in astrocytesthe most abundant cell type in the braintoward the discovery of more effective treatments for brain edema!

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

14 SBIR/STTR records share this UEI (2007–2020). Reported award amounts total $7,478,355. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.